

Charles H Lawrie

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6645687/charles-h-lawrie-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94 papers	4,894 citations	32 h-index	69 g-index
99 ext. papers	5,506 ext. citations	6.3 avg, IF	5.49 L-index

#	Paper	IF	Citations
94	MicroRNA involvement in invasion and metastasis 2022 , 47-62		
93	Radiological outcomes following manual and robotic-assisted unicompartmental knee arthroplasty. <i>Bone & Joint Open</i> , 2021 , 2, 191-197	2.8	1
92	MicroRNAs in Metastasis and the Tumour Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
91	Pre-targeting with ultra-small nanoparticles: boron carbon dots as drug candidates for boron neutron capture therapy. <i>Journal of Materials Chemistry B</i> , 2021 , 9, 410-420	7.3	7
90	Heparin length in the coating of extremely small iron oxide nanoparticles regulates theranostic applications. <i>Nanoscale</i> , 2021 , 13, 842-861	7.7	3
89	Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC). <i>Cancers</i> , 2021 , 13,	6.6	2
88	The Urinary Transcriptome as a Source of Biomarkers for Prostate Cancer. <i>Cancers</i> , 2020 , 12,	6.6	8
87	Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study. <i>International Journal of Cancer</i> , 2020 , 147, 1315-1324	7.5	8
86	Circular RNAs and cancer: Opportunities and challenges. <i>Advances in Clinical Chemistry</i> , 2020 , 99, 87-146	5.8	4
85	Therapeutic Pretargeting with Gold Nanoparticles as Drug Candidates for Boron Neutron Capture Therapy. <i>Particle and Particle Systems Characterization</i> , 2020 , 37, 2000200	3.1	5
84	An Integrative Omics Approach Reveals Involvement of in Hepatic Metastatic Progression of Colorectal Cancer. <i>Cancers</i> , 2020 , 12,	6.6	2
83	The circulating transcriptome as a source of cancer liquid biopsy biomarkers. <i>Seminars in Cancer Biology</i> , 2019 , 58, 100-108	12.7	53
82	Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia. <i>Biomarker Insights</i> , 2019 , 14, 1177271919846454	3.5	50
81	MicroRNAs and Metastasis. <i>Cancers</i> , 2019 , 12,	6.6	8
80	The Circulating Transcriptome as a Source of Biomarkers for Melanoma. <i>Cancers</i> , 2019 , 11,	6.6	28
79	CircRNAs and cancer: Biomarkers and master regulators. <i>Seminars in Cancer Biology</i> , 2019 , 58, 90-99	12.7	177
78	High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma. <i>Annals of Diagnostic Pathology</i> , 2018 , 34, 27-30	2.2	7

77	Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma. <i>Annals of Diagnostic Pathology</i> , 2018 , 34, 89-93	2.2	9
76	Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms. <i>Journal of Molecular Diagnostics</i> , 2018 , 20, 34-45	5.1	16
75	The Role of Chemically Modified DNA in Discrimination of Single-Point Mutation through Plasmon-Based Colorimetric Assays. <i>ACS Applied Nano Materials</i> , 2018 , 1, 3741-3746	5.6	5
74	Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy. <i>Pathology Research and Practice</i> , 2018 , 214, 1110-1114	3.4	20
73	MicroRNAs as Biomarkers of B-cell Lymphoma. <i>Biomarker Insights</i> , 2018 , 13, 1177271918806840	3.5	18
72	Nanoparticle-Based Discrimination of Single-Nucleotide Polymorphism in Long DNA Sequences. <i>Bioconjugate Chemistry</i> , 2017 , 28, 903-906	6.3	13
71	DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas. <i>Pathology</i> , 2017 , 49, 731-739	1.6	12
70	Blocking probe as a potential tool for detection of single nucleotide DNA mutations: design and performance. <i>Nanoscale</i> , 2017 , 9, 16205-16213	7.7	3
69	miRNAs in B-cell lymphoma: Molecular mechanisms and biomarker potential. <i>Cancer Letters</i> , 2017 , 405, 79-89	9.9	16
68	Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients. <i>PLoS ONE</i> , 2017 , 12, e0181711	3.7	25
67	SOX9 Elevation Acts with Canonical WNT Signaling to Drive Gastric Cancer Progression. <i>Cancer Research</i> , 2016 , 76, 6735-6746	10.1	79
66	Sensitivity Limit of Nanoparticle Biosensors in the Discrimination of Single Nucleotide Polymorphism. <i>ACS Sensors</i> , 2016 , 1, 1110-1116	9.2	17
65	Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC). <i>F1000Research</i> , 2016 , 5, 2020	3.6	9
64	New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	162
63	Stratification and therapeutic potential of PML in metastatic breast cancer. <i>Nature Communications</i> , 2016 , 7, 12595	17.4	26
62	Conjugated Polymers As Molecular Gates for Light-Controlled Release of Gold Nanoparticles. <i>ACS Applied Materials & Interfaces</i> , 2015 , 7, 15692-5	9.5	5
61	Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. <i>Nature Communications</i> , 2015 , 6, 8428	17.4	39
60	Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Experimental and Molecular Pathology</i> , 2015 , 99, 537-45	4.4	12

59	Written in Blood: Kissing Disease miRNAs Could Predict Outcome of Patients With Chronic Lymphocytic Leukaemia. <i>EBioMedicine</i> , 2015 , 2, 489-90	8.8	
58	The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids. <i>Journal of Cellular and Molecular Medicine</i> , 2015 , 19, 2307-23	5.6	64
57	MicroRNAs as B-cell lymphoma biomarkers. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2015 , 25	2.6	1
56	MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential. <i>Current Genomics</i> , 2015 , 16, 349-58	2.6	18
55	Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. <i>Nature Genetics</i> , 2014 , 46, 176-181	36.3	475
54	Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes. <i>Journal of Pathology</i> , 2014 , 232, 32-42	9.4	39
53	Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. <i>Leukemia</i> , 2014 , 28, 362-72	10.7	24
52	MicroRNAs and Blood Cancers 2014 , 129-153		
51	Circulating MicroRNAs as Cellular Messengers 2013 , 589-605		
50	MicroRNAs and lymphomagenesis: a functional review. <i>British Journal of Haematology</i> , 2013 , 160, 571-81	4.5	58
49	MicroRNAs in hematological malignancies. <i>Blood Reviews</i> , 2013 , 27, 143-54	11.1	45
48	Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2013 , 3, e152	7	42
47	MicroRNAs: A Brief Introduction 2013 , 1-24		1
46	Circulating MicroRNAs as Non-Invasive Biomarkers 2013 , 567-588		1
45	The MicroRNA Decalogue of Cancer Involvement 2013 , 199-221		
44	Regulation of Hypoxia Responses by MicroRNA Expression 2013 , 267-285		
43	MicroRNAs as Oncogenes and Tumor Suppressors 2013 , 223-243		3
42	MicroRNAs in Platelet Production and Activation 2013 , 101-116		1

41	MicroRNA Expression in Avian Herpesviruses 2013 , 137-151		
40	MicroRNA in B-Cell Non-Hodgkin's Lymphoma: Diagnostic Markers and Therapeutic Targets 2013 , 403-418		
39	MicroRNA Expression in Cutaneous T-Cell Lymphomas 2013 , 449-461		
38	Release of MicroRNA-Containing Vesicles Can Stimulate Angiogenesis and Metastasis in Renal Carcinoma 2013 , 607-622		
37	MicroRNAs in Diffuse Large B-Cell Lymphoma 2013 , 419-433		
36	Transcriptional repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of Multiple Myeloma. <i>PLoS ONE</i> , 2013 , 8, e66121	3.7	20
35	Therapeutic strategies targeting glioblastoma stem cells. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2013 , 8, 216-27	2.6	14
34	Primary cutaneous anaplastic large cell lymphoma shows a distinct miRNA expression profile and reveals differences from tumor-stage mycosis fungoides. <i>Experimental Dermatology</i> , 2012 , 21, 632-4	4	39
33	Inter- and intra-observational variability in immunohistochemistry: a multicentre analysis of diffuse large B-cell lymphoma staining. <i>Histopathology</i> , 2012 , 61, 18-25	7.3	18
32	Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?. <i>Blood Cancer Journal</i> , 2012 , 2, e83	7	27
31	miRNA expression profiling of mycosis fungoides. <i>Molecular Oncology</i> , 2011 , 5, 273-80	7.9	79
30	Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens. <i>PLoS ONE</i> , 2011 , 6, e23916	3.7	10
29	CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2011 , 96, 78-86	6.6	8
28	MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. <i>Biology Direct</i> , 2011 , 6, 23	7.2	74
27	Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells. <i>British Journal of Haematology</i> , 2010 , 149, 221-30	4.5	31
26	Comparison of Choi and Hans algorithms by immunohistochemistry and quantitative reverse transcriptase-PCR - letter. <i>Clinical Cancer Research</i> , 2010 , 16, 3805-6	12.9	1
25	microRNA expression in erythropoiesis and erythroid disorders. <i>British Journal of Haematology</i> , 2010 , 150, 144-51	4.5	36
24	MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. <i>Blood</i> , 2010 , 116, 1105-13	2.2	117

23	Differential expression of microRNAs in Marek's disease virus-transformed T-lymphoma cell lines. <i>Journal of General Virology</i> , 2009 , 90, 1551-1559	4.9	54
22	Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 1248-60	5.6	132
21	Aberrant expression of microRNA biosynthetic pathway components is a common feature of haematological malignancy. <i>British Journal of Haematology</i> , 2009 , 145, 545-8	4.5	13
20	Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2009 , 146, 396-407	4.5	25
19	MicroRNA expression in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2009 , 147, 398-403	4.5	9
18	Expression profiling of persistent polyclonal B-cell lymphocytosis suggests constitutive expression of the AP-1 transcription complex and downregulation of Fas-apoptotic and TGFbeta signalling pathways. <i>Leukemia</i> , 2009 , 23, 581-3	10.7	5
17	MicroRNA expression in lymphocyte development and malignancy. <i>Leukemia</i> , 2008 , 22, 1440-6	10.7	76
16	Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2008 , 141, 672-5	4.5	1389
15	MicroRNA expression in lymphoid malignancies: new hope for diagnosis and therapy?. <i>Journal of Cellular and Molecular Medicine</i> , 2008 , 12, 1432-44	5.6	48
14	MicroRNA profile of Marek's disease virus-transformed T-cell line MSB-1: predominance of virus-encoded microRNAs. <i>Journal of Virology</i> , 2008 , 82, 4007-15	6.6	115
13	MicroRNA expression in lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 1363-74	5.4	41
12	MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. <i>International Journal of Cancer</i> , 2007 , 121, 1156-61	7.5	328
11	MicroRNAs and haematology: small molecules, big function. <i>British Journal of Haematology</i> , 2007 , 137, 503-12	4.5	105
10	Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. <i>British Journal of Haematology</i> , 2007 , 139, 578-89	4.5	130
9	Marek's disease virus type 2 (MDV-2)-encoded microRNAs show no sequence conservation with those encoded by MDV-1. <i>Journal of Virology</i> , 2007 , 81, 7164-70	6.6	87
8	MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas. <i>British Journal of Haematology</i> , 2007 , 138, 479-86	4.5	24
7	Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling. <i>International Journal of Cancer</i> , 2006 , 118, 3161-6	7.5	41
6	Investigation of the mechanisms of anti-complement activity in Ixodes ricinus ticks. <i>Molecular Immunology</i> , 2005 , 42, 31-8	4.3	32

5	Susceptibility of mosquito and tick cell lines to infection with various flaviviruses. <i>Medical and Veterinary Entomology</i> , 2004 , 18, 268-74	2.4	43
4	IgG responses to salivary gland extract of Ixodes ricinus ticks vary inversely with resistance in naturally exposed sheep. <i>Medical and Veterinary Entomology</i> , 2002 , 16, 186-92	2.4	20
3	Antigenic profile of Ixodes ricinus: effect of developmental stage, feeding time and the response of different host species. <i>Parasite Immunology</i> , 2001 , 23, 549-56	2.2	13
2	Ixodes ticks: serum species sensitivity of anticomplement activity. <i>Experimental Parasitology</i> , 1999 , 93, 207-14	2.1	61
1	Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC). <i>F1000Research</i> , 5, 2020	3.6	4